vs
Side-by-side financial comparison of Alector, Inc. (ALEC) and QIAGEN N.V. (QGEN). Click either name above to swap in a different company.
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for neurodegenerative diseases. Its product pipeline targets unmet medical needs including Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, and it collaborates with global pharmaceutical partners to advance candidate therapies through clinical trials.
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located ...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.2M | — | ||
| Q3 25 | $3.3M | — | ||
| Q2 25 | $7.9M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $54.2M | — | ||
| Q3 24 | $15.3M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $15.9M | — |
| Q4 25 | $-37.3M | — | ||
| Q3 25 | $-34.7M | — | ||
| Q2 25 | $-30.5M | — | ||
| Q1 25 | $-40.5M | — | ||
| Q4 24 | $-2.1M | — | ||
| Q3 24 | $-42.2M | — | ||
| Q2 24 | $-38.7M | — | ||
| Q1 24 | $-36.1M | — |
| Q4 25 | -634.4% | — | ||
| Q3 25 | -1153.6% | — | ||
| Q2 25 | -433.6% | — | ||
| Q1 25 | -1216.5% | — | ||
| Q4 24 | -13.4% | — | ||
| Q3 24 | -315.7% | — | ||
| Q2 24 | -302.4% | — | ||
| Q1 24 | -275.0% | — |
| Q4 25 | -597.5% | — | ||
| Q3 25 | -1063.4% | — | ||
| Q2 25 | -387.7% | — | ||
| Q1 25 | -1101.6% | — | ||
| Q4 24 | -3.8% | — | ||
| Q3 24 | -275.2% | — | ||
| Q2 24 | -256.4% | — | ||
| Q1 24 | -227.0% | — |
| Q4 25 | $-0.34 | — | ||
| Q3 25 | $-0.34 | — | ||
| Q2 25 | $-0.30 | — | ||
| Q1 25 | $-0.41 | — | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.43 | — | ||
| Q2 24 | $-0.40 | — | ||
| Q1 24 | $-0.38 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
